All In Biotech

Drug Trial Radar · NCT06427811

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

A Prospective, Multicenter, Single-arm, Open-label, Phase IV, Post-authorization Interventional Study to Assess the Safety and Efficacy of Asciminib in Indian Patients With Ph+ CML-CP (Without T315I Mutation), Previously Treated With Two or More Tyrosine Kinase Inhibitors and Ph+ CML-CP With T315I Mutation

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Nov 28, 2024

Primary completion

Mar 18, 2026

Study completion Mar 18, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) per the India Prescribing Information (PI). The purpose of this prospective, multicenter, single-arm, open-label, Phase IV study is, therefore, to confirm the safety and efficacy of Asciminib in Indian patients with Ph+ CML-CP (without threonine-315 residue with isoleucine \[T315I\] mutation), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) and patients with Ph+ CML-CP with T315I mutation.

Conditions

  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Interventions

  • AsciminibDrug

    Film-coated tablets with 40 mg dose strength taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse events(AEs)/serious AEs (SAEs) in participants with Ph+ CML-CP without T315I mutationTime frame: up to 6 months
  2. Frequency and severity of AEs/SAEs in participants with Ph+ CML-CP with T315I mutationTime frame: up to 6 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Cuttack, India

  • Novartis Investigative Site

    Guwahati, India

  • Novartis Investigative Site

    Ahmedabad, Gujarat, India

  • Novartis Investigative Site

    Ahmedabad, Gujrat, India

  • Novartis Investigative Site

    Bengaluru, Karnataka, India

  • Novartis Investigative Site

    Trivandrum, Kerala, India

  • Novartis Investigative Site

    Pune, Maharashtra, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Hyderabad, Telangana, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.